Feasibility Study of a Nurse Intervention to Impact Mucositis Severity and Prevent Dehydration

September 11, 2019 updated by: Raphael Yechieli, University of Miami

Feasibility Study of a Nurse-Delivered Telephone Intervention To Impact Mucositis Symptom Severity and Prevent Dehydration in Lung and Head/Neck Cancer Patients Undergoing Chemoradiation: A Pilot Study

This is a descriptive mixed method pilot study to determine the feasibility of a tailored nurse-delivered telephone intervention designed to impact mucositis symptom severity and prevent dehydration in lung and head/neck cancer patients undergoing chemoradiation, therefore reducing overall symptom severity and improving quality of life. Secondary purposes for this study are to investigate if the nursing intervention can decrease lung and head/neck cancer patients' unscheduled medical visits between chemoradiation treatments.

Study Overview

Study Type

Interventional

Enrollment (Actual)

11

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami Sylvester Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Non-Small Cell or Limited Stage Small Cell Lung Cancer OR Head & Neck Cancer
  • Over 18 years old
  • Eligible for concurrent Chemoradiation in the first line setting
  • Eastern Cooperative Group 0-2 (able to complete Activity of Daily Living (ADLs) independently or with assistive device only)
  • Able to read & write English or Spanish

Exclusion Criteria:

  • Under 18 years old
  • Underlying Anxiety or Depression (must pass screening tools)
  • Medically Diagnosed with a Cognitive Impairment
  • No prior Chemotherapy or Radiation treatment
  • No access to a telephone
  • Blind or Deaf or Illiterate
  • Requires assistance with Self-Care ADLs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SMENC Group

The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.

During the telephone call, the patient will report the use of the Drinks Diary.

The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the "Cancer Treatment Symptom Management Education Toolkit" geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration.
The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants that completed calls
Time Frame: 6 weeks
Defined as the number of participants that completed 80% of the total 12 calls.
6 weeks
Duration of phone call
Time Frame: 6 weeks
Amount of time of the patient daily phone call (in minutes).
6 weeks
Percentage of patients using Intervention materials
Time Frame: 6 weeks
Percentage of the patients who reports using the interventions materials (SxM Toolkit and Drinks Diary).
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Attrition Rate
Time Frame: 6 weeks
Attrition rate will be comprised of those study participants who drop out of the study and be computed as a percent.
6 weeks
Study Completion Rate
Time Frame: 6 weeks
Length of time spent in the study will be expressed as a percent and it is expected that the participants will complete 75% of their planned chemoradiation treatments.
6 weeks
Participant Satisfaction
Time Frame: 6 weeks
Qualitative analysis of a customized Semi-Structured Interview
6 weeks
Change in severity of mucositis
Time Frame: 6 weeks

Mucositis severity will be measured daily by the Oral Mucositis Daily Questionnaire (OMDQ).

A score of 0 equals no mucositis severity and high mucositis severity equals a score of 4 on question 2.

6 weeks
Change in overall symptom severity
Time Frame: 10 weeks

The M.D. Anderson Symptom Inventory - Lung Cancer / Head & Neck Cancer(MDASI-LC; MDASI-HN) will be used to measure overall severity.

The total MDASI-LC; HN score will be used in the analysis of overall symptom severity. Friedman's test is the test statistic that will be used to measure the effect of the intervention on overall symptom severity per cycle of chemoradiation treatment.

10 weeks
Change in quality of life
Time Frame: 10 weeks
Health Related Quality of Life (HRQoL) will be measured by the Functional Assessment of Cancer Therapy - Lung and Head & Neck versions (FACT-L; FACT-H&N respectively ). The FACT-L & FACT H&N are both a five domain, 36 item self-report instrument scored on a 5 point Likert scale (zero to 4) with a score range of 0-144; the higher the score = higher HRQoL.
10 weeks
Unscheduled Medical Visits
Time Frame: 6 weeks
Number of unplanned medical visits made by the patient to the Oncologist for intravenous fluid administration.
6 weeks
Influence of Nurse-Delivered Telephone Intervention on Self-Efficacy
Time Frame: 10 weeks
The adapted Chronic Disease Self-Efficacy Scale (CDSES) was developed by combining the subscales of Manage Disease in General Scale and the Symptoms Scale for a combined 10 item scale to measure the concept of perceived self-efficacy. Each item is scored 0 to 8; with the higher combined sum score equating to a higher perceived self-efficacy in the participant.
10 weeks
Influence of Nurse-Delivered Telephone Intervention on Symptom Self-Management
Time Frame: 10 weeks
The Partners in Health Scale (PIHS) was designed to measure adherence to treatment, knowledge of disease, management of side effects and management of signs and symptoms over time. The 12 item questionnaire scores each question among the domain categories on a 9 point scale from 0-8 and the higher sum score reflects a higher self-management in the participant.
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Raphael Yechieli, MD, University of Miami

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 29, 2018

Primary Completion (Actual)

August 22, 2019

Study Completion (Actual)

August 22, 2019

Study Registration Dates

First Submitted

January 24, 2018

First Submitted That Met QC Criteria

January 24, 2018

First Posted (Actual)

January 31, 2018

Study Record Updates

Last Update Posted (Actual)

September 13, 2019

Last Update Submitted That Met QC Criteria

September 11, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Cancer

Clinical Trials on Symptom Management Education and Nurse Coaching

Subscribe